Debra Davis, MD
Internal Medicine · Tuscaloosa, ALNPI 1508933748
Payments from drug & device makers
Across 714 payments — averaging $16.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$2K
- Lilly USA, LLC$2K
- Abbott$1K
- Sanofi-aventis U.S. LLC$1K
- AbbVie$723
- Dexcom, Inc.$661
- plus $5K from 34 others
What the payments were for
- Food & beverage$11,60598%
- Education$2002%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 146 | $2,035 |
| Lilly USA, LLC | 99 | $1,541 |
| Abbott | 65 | $1,032 |
| Sanofi-aventis U.S. LLC | 55 | $1,027 |
| AbbVie(2 entities) | 46 | $723 |
| Dexcom, Inc. | 32 | $661 |
| Corcept Therapeutics | 30 | $553 |
| Amarin Pharma, Inc. | 27 | $410 |
| Merck | 23 | $339 |
| Bayer | 19 | $328 |
| Johnson & Johnson | 28 | $327 |
| AstraZeneca | 5 | $284 |
| Astellas Pharma US Inc | 7 | $273 |
| Boehringer Ingelheim | 16 | $252 |
| Amgen | 16 | $237 |
| Esperion Therapeutics, Inc. | 10 | $172 |
| Mannkind Corporation | 11 | $165 |
| Radius Health, Inc. | 9 | $154 |
| Novartis | 8 | $143 |
| Medtronic | 7 | $126 |
| Exact Sciences | 6 | $120 |
| Sunovion Pharmaceuticals Inc. | 6 | $114 |
| Pfizer | 5 | $100 |
| Xeris Pharmaceuticals, Inc. | 5 | $92 |
| Tandem Diabetes Care, Inc. | 4 | $88 |
| Insulet Corporation | 3 | $72 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 4 | $68 |
| Ultragenyx Pharmaceutical Inc. | 3 | $53 |
| Lifescan, Inc. | 3 | $50 |
| BD | 1 | $33 |
| GSK | 2 | $31 |
| Otsuka America Pharmaceutical, Inc. | 2 | $31 |
| OPKO Pharmaceuticals, LLC | 2 | $29 |
| Shire North American Group Inc | 2 | $29 |
| Genentech USA, Inc. | 2 | $25 |
| IBSA Pharma Inc. | 1 | $23 |
| Sumitomo Pharma America, Inc. | 1 | $18 |
| Arbor Pharmaceuticals, Inc. | 1 | $17 |
| Shield Therapeutics Inc | 1 | $17 |
| Endo Pharmaceuticals Inc. | 1 | $13 |
How this compares
$11,805 in reported general payments places this provider in the 90th percentile of 1,533 internal medicine providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 148 | $149,436 |
| EliquisApixaban | 134 | $105,906 |
| JanuviaSitagliptin Phosphate | 133 | $104,115 |
| OzempicSemaglutide | 75 | $89,799 |
| JardianceEmpagliflozin | 56 | $44,697 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 18 | $19,789 |
| TrulicityDulaglutide | 17 | $14,971 |
| EntrestoSacubitril/Valsartan | 15 | $14,864 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 78 | $14,384 |
| XareltoRivaroxaban | 16 | $13,611 |
| Levothyroxine Sodium | 565 | $6,900 |
| SynthroidLevothyroxine Sodium | 66 | $5,772 |
| Cyclosporine | 12 | $5,632 |
| LinzessLinaclotide | 11 | $5,599 |
| GemtesaVibegron | 11 | $5,337 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $1,541 | $164,406165 claims |
| MerckJanuvia, Janumet Xr | $339 | $123,904151 claims |
| PfizerEliquis, Paxlovid | $100 | $108,765151 claims |
| Novo NordiskOzempic | $2,035 | $89,79975 claims |
| Boehringer IngelheimJardiance | $252 | $44,69756 claims |
| NovartisEntresto | $143 | $14,86415 claims |
| Johnson & JohnsonXarelto | $327 | $13,61116 claims |
| AbbVieSynthroid, Linzess | $723 | $11,37277 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $18 | $5,33711 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,533 internal medicine providers in Alabama.
Other internal medicine in Tuscaloosa
- Nancy Tactuk RomanenkoTuscaloosa$21K
- Harry StuddardMobile$12.9M
- Almena FreeAnniston$12.7M
- Hayes WilliamsVestavia$10.4M
- David DeatkineBirmingham$8M
- James SullivanBirmingham$6M
- Ramy TomaBirmingham$5.1M
- Barry McLeanHomewood$4M
- William KirbyBirmingham$2.3M
- Saadat AnsariHuntsville$2.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.